Generic Drug

Everything

Bestselling in Generic Drug

Skip carousel

carousel previous carousel next

Everything About Generic Drug

Skip carousel

carousel previous carousel next

Alpex Pharma et. al. v. Zydus Pharmaceuticals et. al.
Author PriorSmart
SENATE HEARING, 109TH CONGRESS - THE GENERIC DRUG MAZE: SPEEDING ACCESS TO AFFORDABLE LIFE-SAVING DRUGS
Author Scribd Government Docs
Oral Drug Delivery Technology
Author Aukunuru Jithan
Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)
Author Martin a. Voet
09-24-15 Edition
Author San Mateo Daily Journal
NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview
Author Swarnlata Saraf
Demonizing Drugmakers: The Political Assault on the Pharmaceutical Industry, Cato Policy Analysis No. 475
Author Cato Institute
Fatal Side Effects: Medicine patents under the microscope
Author Oxfam
Generic Drugs: A Consumer’S Self-Defense Guide
Author Clifford L. Nilsen
Fatal Side Effects: Medicine patents under the microscope
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
United States v. Articles of Drug, Etc. Appeal of the Lannett Company, Inc, 585 F.2d 575, 3rd Cir. (1978)
Author Scribd Government Docs
Merck Sharp & Dohme Corp. V. Sandoz Inc.
Author PriorSmart
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
Dare to Lead: Public health and company wealth
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
SENATE HEARING, 109TH CONGRESS - INCREASING GENERIC DRUG USE: SAVINGS FOR SENIORS AND MEDICARE
Author Scribd Government Docs
HOUSE HEARING, 111TH CONGRESS - PAY TO DELAY: ARE PATENT SETTLEMENTS THAT DELAY GENERIC DRUG MARKET ENTRY ANTICOMPETITIVE?
Author Scribd Government Docs
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam
Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines
Author Oxfam

Recently Added

Skip carousel

carousel previous carousel next

Explore more in Generic Drug

Language

Generic Drug

Bestselling in Generic Drug

Generic Alternatives to Prescription Drugs: Your Guide to Buying Effective Drugs at Cost-Saving Prices

Bottle of Lies: The Inside Story of the Generic Drug Boom

Senate Aging Report Sudden Price Spikes in Off Patent Prescription Drugs

Bill Ackman Allergan Presentation

Otsuka Pharmaceutical v. Wockhardt Bio et. al.

Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)

Janssen Products et. al. v. Lupin et. al.

AbbVie et. al. v. Amneal Pharmaceuticals et. al.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Otsuka Pharmaceutical v. Torrent Pharmaceuticals et. al.

Fatal Side Effects: Medicine patents under the microscope

Make Vital Medicines Available for Poor People: Dominican Republic

Forest Laboratories et. al. v. Torrent Pharmaceuticals et. al.

Generic Drugs: A Consumer’S Self-Defense Guide

Fatal Side Effects: Medicine patents under the microscope

Granutec v. Genpharm, 4th Cir. (1998)

Unimed Pharmaceuticals LLC et. al.

Niaspan Lawsuit Complaint

Dare to Lead: Public health and company wealth

Sandoz v. Novo Nordisk et. al.

Ferring v. Mylan et. al.

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

09-24-15 Edition

SENATE HEARING, 108TH CONGRESS - IMPORTATION OF PRESCRIPTION DRUGS

Unimed Pharmaceuticals et. al. v. Perrigo Company et. al.

Apotex et. al. v. Pfizer et. al.

Demonizing Drugmakers: The Political Assault on the Pharmaceutical Industry, Cato Policy Analysis No. 475

Warner Chilcott Company v. Zydus Pharmaceuticals et. al.

Short Idea on Lannett

Amarin Pharma et. al. v. Dr. Reddy's Laboratories et. al.

Everything About Generic Drug

Alpex Pharma et. al. v. Zydus Pharmaceuticals et. al.

SENATE HEARING, 109TH CONGRESS - THE GENERIC DRUG MAZE: SPEEDING ACCESS TO AFFORDABLE LIFE-SAVING DRUGS

Oral Drug Delivery Technology

Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)

09-24-15 Edition

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Demonizing Drugmakers: The Political Assault on the Pharmaceutical Industry, Cato Policy Analysis No. 475

Fatal Side Effects: Medicine patents under the microscope

Generic Drugs: A Consumer’S Self-Defense Guide

Fatal Side Effects: Medicine patents under the microscope

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

United States v. Articles of Drug, Etc. Appeal of the Lannett Company, Inc, 585 F.2d 575, 3rd Cir. (1978)

Merck Sharp & Dohme Corp. V. Sandoz Inc.

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Dare to Lead: Public health and company wealth

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

SENATE HEARING, 109TH CONGRESS - INCREASING GENERIC DRUG USE: SAVINGS FOR SENIORS AND MEDICARE

HOUSE HEARING, 111TH CONGRESS - PAY TO DELAY: ARE PATENT SETTLEMENTS THAT DELAY GENERIC DRUG MARKET ENTRY ANTICOMPETITIVE?

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Recently Added

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Generic Drugs: A Consumer’S Self-Defense Guide

Make Vital Medicines Available for Poor People: Dominican Republic

Fatal Side Effects: Medicine patents under the microscope

Fatal Side Effects: Medicine patents under the microscope

Dare to Lead: Public health and company wealth

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices

Fatal Side Effects: Medicine patents under the microscope

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices

All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines